Mereo Biopharma Investor Relations Material
Latest events
Study Update
Mereo Biopharma
Q1 2025
13 May, 2025
Q4 2024
26 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mereo Biopharma Group
Access all reports
Mereo Biopharma Group plc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare diseases and oncology. The company has a diverse portfolio of product candidates in various stages of clinical development, including treatments for conditions such as osteogenesis imperfecta, Alpha-1 anti-trypsin deficiency, and different types of cancer. Among its leading candidates are etigilimab, an antibody designed for tumor treatment, and alvelestat, intended for Alpha-1 anti-trypsin deficiency. Founded in 2015, Mereo Biopharma Group plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
MREO
Country
🇺🇸 United States